A new analysis from King's College London, published in The Lancet Diabetes & Endocrinology, challenges one of the most repeated pieces of advice given to people living with prediabetes: that eating better and moving more is enough to protect the heart. The research found that actually reversing prediabetes — pushing blood glucose back into the normal range — was associated with a 58% lower risk of cardiovascular death or hospitalisation for heart failure, and a 42% lower risk of heart attack, stroke and other major cardiovascular events. Lifestyle changes that don't achieve that reversal, the data suggests, don't meaningfully move the cardiovascular needle.
That finding lands awkwardly against the standard public health message. For two decades, people told they were prediabetic have been handed pamphlets about walking more, losing 5% of their body weight, and cutting back on refined carbs — with the implicit promise that doing so would protect their hearts. The new analysis says that promise was incomplete. The lifestyle changes matter, but the outcome that matters is the glucose number, not the effort.
What the study actually measured
Led by Dr Andreas Birkenfeld of King's College London and University Hospital Tübingen, the researchers pooled data from two of the longest-running prediabetes cohorts in the world: the US Diabetes Prevention Program Outcomes Study (DPPOS) and the Chinese DaQing Diabetes Prevention Outcomes Study (DaQingDPOS). The US arm followed participants for around 20 years; the Chinese arm tracked them for 30. That length of follow-up is unusual — most diabetes prevention research wraps up after three to six years, well before cardiovascular events have time to accumulate.
The comparison the researchers cared about was not lifestyle group versus control group. It was the group whose blood glucose actually normalised versus the group whose glucose stayed in the prediabetic range, regardless of how they got there. People who achieved remission saw a 58% reduction in cardiovascular death or heart failure hospitalisation, and a 42% reduction in major adverse cardiovascular events including heart attack and stroke. The benefit held across both the US and Chinese populations and persisted for decades after the glucose normalised.
People who made lifestyle changes but didn't achieve remission? Their cardiovascular outcomes looked essentially the same as people who made no changes at all.
Why the distinction matters
This is a subtle but consequential reframing. The conventional message — that lifestyle change protects your heart — collapses two different things into one. There is the input (exercise, diet, weight loss) and there is the biological endpoint (normalised blood glucose). Public health communication has tended to assume the input automatically produces the endpoint, and that the input itself carries cardiovascular benefit even if the endpoint isn't reached.
"This study challenges one of the biggest assumptions in modern preventative medicine," Birkenfeld said in the King's College London announcement. "For years, people with prediabetes have been told that losing weight, exercising more and eating healthier will protect them from heart attacks and early death. While these lifestyle changes are unquestionably valuable, the evidence does not support that they reduce heart attacks or mortality in people with prediabetes."
The implication: a person who walks daily, cuts ultra-processed food, drops ten pounds, and still has an HbA1c in the prediabetic range is not getting the heart protection they think they are. The protective effect is tied to the glucose number, not the virtue of the routine.
The scale of who this affects
Prediabetes is not a niche diagnosis. Around one in five UK adults has diabetes or prediabetes; in the US, the figure exceeds one in three; in China, it reaches four in ten. Globally, more than a billion people are estimated to have prediabetes. The condition is essentially a demographic baseline now in much of the world — a function of how people eat, how they move, how they sleep, and how much metabolic stress sits in the systems they live inside.
Which means the question of whether lifestyle change alone protects the heart, or whether the protection only kicks in at remission, isn't an academic distinction. It changes what doctors should tell patients. It changes what counts as a successful intervention. And it raises uncomfortable questions about how much current prevention guidance is optimised for effort rather than outcome.
What this means for plant-forward eating advice
None of this is an argument against eating more plants, moving more, or sleeping better. The lifestyle changes are still associated with a long list of other benefits — better blood pressure, lower inflammation, improved mood, reduced cancer risk. These interventions remain valuable.
But the research does suggest the goal of dietary change in prediabetes should be reframed. The point is not the dietary pattern itself. The point is whether the pattern is intense enough, sustained enough, and personalised enough to actually move fasting glucose and HbA1c back into the normal range. A mostly plant-based diet that still includes large amounts of refined carbohydrates and added sugar may not achieve remission. Neither may a low-fat diet that doesn't address total caloric load or meal timing.
This is a useful corrective to the soft-focus version of eat-better-feel-better advice. The body is keeping a specific score. Glucose is one of the metrics on the scoreboard. And the scoreboard, not the effort, is what predicts cardiovascular outcomes.
A fourth pillar of prevention
The broader argument from the King's College London team is that prediabetes remission deserves to sit alongside blood pressure control, cholesterol management, and smoking cessation as a core primary prevention strategy.
That framing carries weight because the other three pillars have decades of guideline-level consensus behind them. Doctors screen for them at every routine visit. Insurance companies price around them. Drug development pipelines orient toward them. Prediabetes, by contrast, has often been treated as a soft warning rather than a target to actively reverse — a yellow light rather than a red one.
The pharmaceutical implications are obvious. GLP-1 drugs like semaglutide and tirzepatide are already being studied for cardiovascular outcomes. If glucose remission itself is the cardioprotective lever, the case for using these drugs earlier — before full-blown type 2 diabetes — gets stronger. So does the case for metformin, bariatric surgery, and intensive dietary interventions that produce measurable metabolic change rather than gradual incremental improvement.
What to ask at the next checkup
For readers who fall into the prediabetic range, the practical takeaway is to push the conversation past general advice.
The questions worth asking a clinician: What's the target number, not just the target behaviour? How will we measure whether the intervention is actually moving glucose? At what point do we add pharmacological support if lifestyle changes alone aren't achieving remission?
The broader cultural shift this implies — from effort-based to outcome-based health advice — will take time to filter through. But the data is now on the table. Reversing prediabetes does something that simply living healthier with prediabetes apparently does not. That's worth knowing before the next bloodwork comes back.
